Inventor · disambiguated record
Marco Ferrara
Also filed as: FERRARA MARCO
27 granted patents·4 pending applications·61 citations·filing 2007–2023
94Inventor score
Files withBOEHRINGER INGELHEIM INT18CENTREXION THERAPEUTICS CORP3ANTIOS THERAPEUTICS INC2CRESCENZI BENEDETTA1CT XION THERAPEUTICS CORP1
Top patents by PatentIndex Score
31 records- 0189US10875867B2Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamideBOEHRINGER INGELHEIM INT·Filed 2019·Granted Dec 29, 2020·3 cites·13 claims
- 0286US9789082B2Somatostatin receptor subtype 4 (SSTR4) agonistsCENTREXION THERAPEUTICS CORP·Filed 2016·Granted Oct 17, 2017·5 cites·38 claims
- 0385US10675268B2Somatostatin receptor subtype 4 (SSTR4) agonistsCENTREXION THERAPEUTICS CORP·Filed 2018·Granted Jun 9, 2020·2 cites·15 claims
- 0485US10166214B2Somatostatin receptor subtype 4 (SSTR4) agonistsCENTREXION THERAPEUTICS CORP·Filed 2017·Granted Jan 1, 2019·4 cites·25 claims
- 0585US9884854B2N-[(pyrimidinylamino)propanyl]-and N[(pyrazinylamino)proppanyl]arylcarboxamidesBOEHRINGER INGELHEIM INT·Filed 2017·Granted Feb 6, 2018·6 cites·4 claims
- 0684US12351584B2Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamideBOEHRINGER INGELHEIM INT·Filed 2023·Granted Jul 8, 2025·0 cites·13 claims
- 0784US10479794B2Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamideBOEHRINGER INGELHEIM INT·Filed 2018·Granted Nov 19, 2019·3 cites·73 claims
- 0883US9371282B2Somatostatin receptor subtype 4 (SSTR4) agonistsCT XION THERAPEUTICS CORP·Filed 2014·Granted Jun 21, 2016·8 cites·48 claims
- 0982US11780827B2Substituted 3-phenoxyazetidin-1-yl-pyrazinesBOEHRINGER INGELHEIM INT·Filed 2021·Granted Oct 10, 2023·1 cites·11 claims
- 1082US8927569B2Macrocyclic compounds as antiviral agentsHARPER STEVEN·Filed 2008·Granted Jan 6, 2015·8 cites·17 claims
- 1181US9328138B2HCV NS3 protease inhibitorsMERCK SHARP & DOHME·Filed 2012·Granted May 3, 2016·8 cites·17 claims
- 1278US10071974B2Morpholine and 1,4-oxazepane amides as somatostatin receptor subtype 4 (SSTR4) agonistsBOEHRINGER INGELHEIM INT·Filed 2015·Granted Sep 11, 2018·2 cites·25 claims
- 1378US8912201B26-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disordersHEINE NIKLAS·Filed 2011·Granted Dec 16, 2014·4 cites·25 claims
- 1476US10183940B2Aryl and heteroaryl-fused tetrahydro-1,4-oxazepine amides as somatostatin receptor subtype 4 (SSTR4) agonistsBOEHRINGER INGELHEIM INT·Filed 2015·Granted Jan 22, 2019·2 cites·15 claims
- 1575US10577336B2Morpholine and 1,4-oxazepane amides as somatostatin receptor subtype 4 (SSTR4) agonistsBOEHRINGER INGELHEIM INT·Filed 2018·Granted Mar 3, 2020·1 cites·12 claims
- 1675US10023575B2Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamideBOEHRINGER INGELHEIM INT·Filed 2016·Granted Jul 17, 2018·1 cites·75 claims
- 1772US11691977B2Cyclic ether derivatives of pyrazolo[1,5-A]pyrimidine-3-carboxyamideBOEHRINGER INGELHEIM INT·Filed 2020·Granted Jul 4, 2023·0 cites·15 claims
- 1872US9012489B2Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicamentGIOVANNINI RICCARDO·Filed 2012·Granted Apr 21, 2015·2 cites·47 claims
- 1964US8314062B2Macrocyclic compounds as antiviral agentsCRESCENZI BENEDETTA·Filed 2007·Granted Nov 20, 2012·1 cites·22 claims
- 2060US12115157B23-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives and the use thereof as medicamentBOEHRINGER INGELHEIM INT·Filed 2022·Granted Oct 15, 2024·0 cites·15 claims
- 2156US11236072B2N-[(pyrimidinylamino)propanyl]-,n-[pyridylamino)propanyl]- and n-[(pyrazinylaminol)propanyl]arylcarboxamidesBOEHRINGER INGELHEIM INT·Filed 2018·Granted Feb 1, 2022·0 cites·5 claims
- 2256US10710984B2N-[(Pyrimidinylamino)propanyl]-and N-[(Pyridinylamino)-propanyl]arylcarboxamidesBOEHRINGER INGELHEIM INT·Filed 2017·Granted Jul 14, 2020·0 cites·8 claims
- 2356US2023076319A1Inhibitors of hepatitis b virusANTIOS THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2455US10787432B2N-[(pyridyloxy)propanyl]benzamidesBOEHRINGER INGELHEIM INT·Filed 2017·Granted Sep 29, 2020·0 cites·4 claims
- 2555US2010099695A1HCV NS3 Protease InhibitorsLIVERTON NIGEL J·Filed 2007·Application pending·0 cites
- 2649US11504382B2Tricyclic inhibitors of Hepatitis B virusANTIOS THERAPEUTICS INC·Filed 2019·Granted Nov 22, 2022·0 cites·15 claims
- 2749US10738031B2N-[(heteroaryloxy)propanyl]heteroaryl carboxamides as antagonists of orexin subtype 1 receptor activityBOEHRINGER INGELHEIM INT·Filed 2017·Granted Aug 11, 2020·0 cites·9 claims
- 2849US10604511B2N-[(pyrazinyloxy)propanyl]benzamides as antagonists of orexin subtype 1 receptor activityBOEHRINGER INGELHEIM INT·Filed 2017·Granted Mar 31, 2020·0 cites·8 claims
- 2941US10392369B2N-[(pyrimidinyloxy)propanyl]benzamidesBOEHRINGER INGELHEIM INT·Filed 2017·Granted Aug 27, 2019·0 cites·11 claims
- 3040US2013040971A16-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disordersBOEHRINGER INGELHEIM INT·Filed 2012·Application pending·0 cites
- 3136US2013178413A1Hcv ns3 protease inhibitorsMCCAULEY JOHN A·Filed 2011·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Marco Ferrara files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →